HRP20210577T1 - Sastavi i načini liječenja i sprječavanje upale - Google Patents
Sastavi i načini liječenja i sprječavanje upale Download PDFInfo
- Publication number
- HRP20210577T1 HRP20210577T1 HRP20210577TT HRP20210577T HRP20210577T1 HR P20210577 T1 HRP20210577 T1 HR P20210577T1 HR P20210577T T HRP20210577T T HR P20210577TT HR P20210577 T HRP20210577 T HR P20210577T HR P20210577 T1 HRP20210577 T1 HR P20210577T1
- Authority
- HR
- Croatia
- Prior art keywords
- nrp1
- polypeptide
- soluble
- cap
- trap
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004207 Neuropilin-1 Human genes 0.000 claims 25
- 108090000772 Neuropilin-1 Proteins 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 101000577540 Homo sapiens Neuropilin-1 Proteins 0.000 claims 6
- 102000050920 human NRP1 Human genes 0.000 claims 6
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000037417 hyperactivation Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
Claims (14)
1. Klopka topivog polipeptida neuropilina-1 (NRP1) građenog od slijeda aminokiselina čiji je identitet najmanje 90 % slijeda domena a1, a2 i b2 nativnog ljudskog NRP1, pri čemu navedena klopka polipeptida NRP1 ne sadrži domenu b2 nativnog ljudskog NRP1.
2. Klopka topivog polipeptida NRP1 prema patentnom zahtjevu 1., pri čemu je navedeni topivi polipeptid NRP1 građen od slijeda aminokiselina čiji je identitet najmanje 95 % domena a1, a2 i b1 nativnog ljudskog NRP1.
3. Klopka topivog polipeptida NRP1 prema patentnom zahtjevu 2., pri čemu je navedeni topivi polipeptid NRP1 građen od slijeda aminokiselina čiji je identitet najmanje 99 % domena a1, a2 i b1 nativnog ljudskog NRP1.
4. Klopka topivog polipeptida NRP1 prema patentnom zahtjevu 3., pri čemu je navedeni topivi polipeptid NRP1 građen od slijeda domena a1, a2 i b1 nativnog ljudskog NRP1.
5. Klopka topivog polipeptida NRP1 prema patentnom zahtjevu 3., pri čemu navedeni topivi polipeptid NRP1 ne sadrži domenu c nativnog ljudskog NRP1.
6. Klopka topivog polipeptida NRP1 prema bilo kojem patentnom zahtjevu od 1. do 5., pri čemu je navedena klopka topivog polipeptida NRP1 građena i od domene fragmenta koji kristalizira (Fc).
7. Klopka topivog polipeptida NRP1 prema patentnom zahtjevu 6., pri čemu je navedena domena Fc građena od slijeda aminokiselina SEQ ID NO: 37.
8. Klopka topivog polipeptida NRP1 prema patentnom zahtjevu 6. ili 7., pri čemu je navedena domena Fc vezana s karboksi-terminusom polipeptida NRP1.
9. Klopka topivog polipeptida NRP1 prema bilo kojem patentnom zahtjevu od 1. do 8. za sprječavanje ili liječenje upalne bolesti ili upalnog stanja koji uključuju hiperaktivaciju prirođenog imunosnog odgovora.
10. Klopka topivog polipeptida NRP1 za upotrebu prema patentnom zahtjevu 9., pri čemu je upalna bolest ili upalno stanje neuroupala.
11. Klopka topivog polipeptida NRP1 za upotrebu prema patentnom zahtjevu 9. ili 10., pri čemu je upalna bolest ili upalno stanje septički šok, artritis, upalna bolest crijeva (IBD), upala kože, dijabetes, uveitis, dijabetička retinopatija, starosna makularna degeneracija (AMD), prematurna retinopatija, multipla skleroza, amiotrofična lateralna skleroza (ALS), smanjena kognitivna sposobnost povezana sa starenjem, Alzheimerova bolest ili moždani udar.
12. Klopka topivog polipeptida NRP1 za upotrebu prema bilo kojem patentnom zahtjevu od 9. do 11., pri čemu navedena klopka topivog polipeptida NRP1 smanjuje i) edem, ii) aktivaciju/jačanje mononuklearnih fagocita, iii) proizvodnju ili lučenje upalnih citokina, iv) patološku neovaskularizaciju, i/ili v) vaskularnu degeneraciju.
13. Klopka topivog polipeptida NRP1 prema bilo kojem patentnom zahtjevu od 1. do 8., pri čemu je navedena klopka topivog polipeptida NRP1 za primjenu na očima.
14. Klopka topivog polipeptida NRP1 prema bilo kojem patentnom zahtjevu od 1. do 8., pri čemu je formula navedene klopke topivog polipeptida NRP1 farmaceutski pripravak s farmaceutski prihvatljivim nosačima ili ekscipijensima.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046459P | 2014-09-05 | 2014-09-05 | |
| EP15838150.9A EP3189074B1 (en) | 2014-09-05 | 2015-09-08 | Compositions and methods for treating and preventing inflammation |
| PCT/CA2015/050862 WO2016033699A1 (en) | 2014-09-05 | 2015-09-08 | Compositions and methods for treating and preventing inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210577T1 true HRP20210577T1 (hr) | 2021-05-28 |
Family
ID=55438956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210577TT HRP20210577T1 (hr) | 2014-09-05 | 2021-04-12 | Sastavi i načini liječenja i sprječavanje upale |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10738122B2 (hr) |
| EP (1) | EP3189074B1 (hr) |
| JP (3) | JP6692816B2 (hr) |
| KR (1) | KR20170044691A (hr) |
| CN (2) | CN107207577B (hr) |
| AU (1) | AU2015311563B2 (hr) |
| CA (1) | CA2960054C (hr) |
| DK (1) | DK3189074T3 (hr) |
| ES (1) | ES2865488T3 (hr) |
| HR (1) | HRP20210577T1 (hr) |
| HU (1) | HUE054204T2 (hr) |
| LT (1) | LT3189074T (hr) |
| PL (1) | PL3189074T3 (hr) |
| PT (1) | PT3189074T (hr) |
| RS (1) | RS61703B1 (hr) |
| SI (1) | SI3189074T1 (hr) |
| WO (1) | WO2016033699A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2865488T3 (es) | 2014-09-05 | 2021-10-15 | Rsem Lp | Composiciones y métodos para el tratamiento y la prevención de la inflamación |
| ES2940360T3 (es) * | 2015-09-22 | 2023-05-05 | Inst Nat Sante Rech Med | Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1 |
| US20200056186A1 (en) * | 2016-09-22 | 2020-02-20 | Rsem, Limited Partnership | Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence |
| JP2020503872A (ja) * | 2017-01-09 | 2020-02-06 | セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー | Ｎｒｐ１の発現を阻害するオリゴヌクレオチド |
| CN110290785A (zh) * | 2017-03-08 | 2019-09-27 | 日清奥利友集团株式会社 | 抗炎症剂、抗炎症用药物组合物、抗炎症用食品组合物 |
| AR122266A1 (es) * | 2019-05-09 | 2022-08-31 | Boehringer Ingelheim Int | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
| WO2020250159A1 (en) | 2019-06-12 | 2020-12-17 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| TW202126685A (zh) * | 2019-09-24 | 2021-07-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 |
| CN112641928A (zh) * | 2019-10-11 | 2021-04-13 | 田中纯美 | 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途 |
| WO2021258218A1 (en) * | 2020-06-26 | 2021-12-30 | Semathera Inc. | Use of soluble nrp1 polypeptides for the treatment of coronavirus infections |
| CN116782920A (zh) * | 2020-07-31 | 2023-09-19 | 常青树治疗公司 | 用于治疗病毒感染的神经毡蛋白和血管紧张素转化酶2融合肽 |
| AU2022341534A1 (en) | 2021-09-08 | 2024-05-02 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Transmembrane peptidic antagonists of plexin-a1 and their therapeutic uses |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
| US5098890A (en) | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
| US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| AUPM516994A0 (en) | 1994-04-20 | 1994-05-12 | Gene Shears Pty. Limited | An in vivo gene expression system |
| US20020132788A1 (en) | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
| US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
| EP1418834A4 (en) * | 2001-07-20 | 2007-04-04 | Sinai School Medicine | METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE |
| WO2003035100A1 (en) * | 2001-09-26 | 2003-05-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Neuropilin as a novel therapeutic target for modulation of immune reponses |
| EP1439192A1 (en) * | 2003-01-15 | 2004-07-21 | Xerion Pharmaceuticals AG | Neuropilin-1 inhibitors |
| AU2006267097A1 (en) | 2005-07-13 | 2007-01-18 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating an inflammatory response |
| UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| AU2007353779B2 (en) * | 2007-05-17 | 2013-11-07 | Genentech, Inc. | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
| CN103193888B (zh) * | 2007-05-17 | 2015-09-09 | 健泰科生物技术公司 | 神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构 |
| WO2009060159A1 (en) | 2007-11-08 | 2009-05-14 | Medigene Limited | Mutated ilt molecules |
| WO2011055550A1 (ja) * | 2009-11-05 | 2011-05-12 | 国立大学法人大阪大学 | 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法 |
| JP2013537172A (ja) * | 2010-09-09 | 2013-09-30 | トリフォイリウム エーピーエス | 血管新生阻害剤の気道投与 |
| US9879075B2 (en) | 2013-02-06 | 2018-01-30 | Yokohama City University and Chiome Bioscience Inc. | Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same |
| AU2014221144B2 (en) | 2013-02-21 | 2018-03-22 | Rsem, Limited Partnership | Inhibition of Sema3A in the prevention and treatment of ocular hyperpermeability |
| ES2865488T3 (es) | 2014-09-05 | 2021-10-15 | Rsem Lp | Composiciones y métodos para el tratamiento y la prevención de la inflamación |
-
2015
- 2015-09-08 ES ES15838150T patent/ES2865488T3/es active Active
- 2015-09-08 WO PCT/CA2015/050862 patent/WO2016033699A1/en active Application Filing
- 2015-09-08 SI SI201531572T patent/SI3189074T1/sl unknown
- 2015-09-08 PT PT158381509T patent/PT3189074T/pt unknown
- 2015-09-08 LT LTEP15838150.9T patent/LT3189074T/lt unknown
- 2015-09-08 RS RS20210437A patent/RS61703B1/sr unknown
- 2015-09-08 JP JP2017531928A patent/JP6692816B2/ja active Active
- 2015-09-08 DK DK15838150.9T patent/DK3189074T3/da active
- 2015-09-08 AU AU2015311563A patent/AU2015311563B2/en active Active
- 2015-09-08 CN CN201580058020.7A patent/CN107207577B/zh active Active
- 2015-09-08 PL PL15838150T patent/PL3189074T3/pl unknown
- 2015-09-08 CN CN202111209393.3A patent/CN113980116A/zh active Pending
- 2015-09-08 KR KR1020177007655A patent/KR20170044691A/ko active IP Right Grant
- 2015-09-08 EP EP15838150.9A patent/EP3189074B1/en active Active
- 2015-09-08 HU HUE15838150A patent/HUE054204T2/hu unknown
- 2015-09-08 CA CA2960054A patent/CA2960054C/en active Active
- 2015-09-08 US US15/507,407 patent/US10738122B2/en active Active
-
2019
- 2019-05-24 US US16/422,273 patent/US10766964B2/en active Active
-
2020
- 2020-04-10 JP JP2020070982A patent/JP7194146B2/ja active Active
- 2020-08-03 US US16/983,185 patent/US11649292B2/en active Active
-
2021
- 2021-04-12 HR HRP20210577TT patent/HRP20210577T1/hr unknown
-
2022
- 2022-12-09 JP JP2022196745A patent/JP2023022308A/ja active Pending
-
2023
- 2023-03-23 US US18/188,707 patent/US20230265199A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6692816B2 (ja) | 2020-05-13 |
| WO2016033699A1 (en) | 2016-03-10 |
| JP7194146B2 (ja) | 2022-12-21 |
| CA2960054C (en) | 2023-11-14 |
| SI3189074T1 (sl) | 2021-08-31 |
| EP3189074A4 (en) | 2018-06-20 |
| HUE054204T2 (hu) | 2021-08-30 |
| US20190359718A1 (en) | 2019-11-28 |
| AU2015311563B2 (en) | 2019-11-28 |
| PL3189074T3 (pl) | 2021-08-02 |
| KR20170044691A (ko) | 2017-04-25 |
| EP3189074A1 (en) | 2017-07-12 |
| CN113980116A (zh) | 2022-01-28 |
| JP2023022308A (ja) | 2023-02-14 |
| US11649292B2 (en) | 2023-05-16 |
| ES2865488T3 (es) | 2021-10-15 |
| US20170283502A1 (en) | 2017-10-05 |
| CN107207577B (zh) | 2021-11-09 |
| JP2017527616A (ja) | 2017-09-21 |
| US20230265199A1 (en) | 2023-08-24 |
| CA2960054A1 (en) | 2016-03-10 |
| PT3189074T (pt) | 2021-04-19 |
| CN107207577A (zh) | 2017-09-26 |
| LT3189074T (lt) | 2021-06-10 |
| JP2020147568A (ja) | 2020-09-17 |
| RS61703B1 (sr) | 2021-05-31 |
| AU2015311563A1 (en) | 2017-03-16 |
| US10738122B2 (en) | 2020-08-11 |
| DK3189074T3 (da) | 2021-04-19 |
| EP3189074B1 (en) | 2021-01-13 |
| US20210061915A1 (en) | 2021-03-04 |
| US10766964B2 (en) | 2020-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210577T1 (hr) | Sastavi i načini liječenja i sprječavanje upale | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| CL2021000088A1 (es) | Anticuerpos anti-cd27 (divisional de solicitud 779-2019). | |
| EA201270824A1 (ru) | Соединения для уменьшения продукции бета-амилоида | |
| PH12019501215A1 (en) | Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid | |
| CR20170060A (es) | Anticuerpos anti tigit | |
| UY35195A (es) | Composiciones y metodos para proteinas de accion prolongada | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| BR112017005917A2 (pt) | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana | |
| BR112014008759A2 (pt) | tratamento de doença ocular | |
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| JP2015517488A5 (hr) | ||
| CO2017000346A2 (es) | Anticuerpos de unión a protofibrillas aβ | |
| JP2013520405A5 (hr) | ||
| MD3261720T2 (ro) | Anticorpi anti-Tau și utilizările acestora | |
| EA201300137A1 (ru) | Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями | |
| MX2014004814A (es) | Compuestos y metodos para mejorar las respuestas inmunes innatas. | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| CL2020001495A1 (es) | Composiciones y método para el tratamiento de enfermedades metabólicas | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| MD20150120A2 (ro) | Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei | |
| EA201391387A1 (ru) | Нейропротекторные пептиды | |
| FI20115870A0 (fi) | Neuroprotektiiviset soluihin tunkeutuvat peptidit |